
|Videos|June 27, 2017
Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast Cancer
Author(s)Harold J. Burstein, MD, PhD
Harold J. Burstein, MD, PhD, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses a survey of how clinicians use genomic assays to assist in decision-making regarding the use of neoadjuvant and adjuvant chemotherapy for patients with ER-positive/HER2-negative early breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
4
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
5































